Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06035939 · ClinicalTrials.gov registry record · NA
SMYLS Multi-site Trial
A NA study of Sickle Cell Disease, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- NA
- Development phase
- 272
- Enrollment target
- 1
- Study location
NCT06035939: Recruiting NA study of Sickle Cell Disease, sponsored by Medical University of South Carolina.
NCT06035939 is a NA study of Sickle Cell Disease that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 272 participants, roughly in line with the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06035939, a NA study of Sickle Cell Disease, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- NA
- Development phase
- 272 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether a web-based intervention using a mobile app is helpful for teens and young adults with sickle cell disease (SCD) in learning how to care for and manage their symptoms.
Primary Outcome
Adolescent and young adult self-report using the Transition Readiness Assessment Questionnaire 5th version (TRAQ-5; 20 items). The instrument consists of 5 scales. Individual item scores range from 1 - 5. Scale scores are determined by calculating the average of the item scores within each scale. Higher scores indicate greater transition readiness and self-management behaviors.
Conditions Studied
Interventions
- BEHAVIORAL Voice Crisis Alert V2
- BEHAVIORAL Electronic educational materials
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
What NCT06035939 shows while recruiting
NCT06035939 is an interventional study that assigns participants to a tested intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Voice Crisis Alert V2 is the first listed.
NCT06035939 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT06035939 about?
NCT06035939 is a clinical study titled "SMYLS Multi-site Trial". The purpose of this study is to find out whether a web-based intervention using a mobile app is helpful for teens and young adults with sickle cell disease (SCD) in learning how to care for and manage their symptoms.
What is the current status of trial NCT06035939?
This trial is currently recruiting. It is a NA study. The enrollment target is 272 participants. The study started on 2024-04-04. Estimated completion is 2028-01-31.
What conditions does trial NCT06035939 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT06035939?
The interventions under investigation include: Voice Crisis Alert V2 (BEHAVIORAL), Electronic educational materials (BEHAVIORAL).
Who is sponsoring clinical trial NCT06035939?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06035939 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06035939's enrollment target sits among peer trials
272 25th of 213 higher than 189 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
- NCT06449638 · 272 participants · NA
Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI